CAS:10212-25-6|Ancitabine Hydrochloride

CAS:10212-25-6|Ancitabine Hydrochloride

Catalogue Number:A637288
Chemical Name:Ancitabine Hydrochloride
Synonyms:2,2′-Anhydro-1-β-D-arabinofuranosylcytosine Hydrochloride; 2,2′-Anhydro-1-β-D-arabinofuranosylcytosine Monohydrochloride; 2,2′-Anhydroarabinosylcytosine Hydrochloride; 2,2′-Anhydroaracytidine Hydrochloride; 2,2′-Anhydrocytidine Hydrochloride; 2,2′-Cyclocytidine Hydrochloride; 2,2′-O-Cyclocytidine Hydrochloride; Ancitabine Hydrochloride; Cyclo-CMP Hydrochloride; Cyclocytidine Hydrochloride; NSC 145668; O2,O2′-Anhydro-1-β-D-arabinofuranosylcytosine Monohydrochloride; O2,O2′-Anhydro-1-β-arabinofuranosylcytosine Hydrochloride; OCTD Hydrochloride; [2R-(2α,3β,3aβ,9aβ)]-2,3,3a,9a-Tetrahydro-3-hydroxy-6-imino-6H-furo[2′,3′:4,5]oxazolo[3,2-a]pyrimidine-2-methanol Monohydrochloride; (2R,3R,3aS,9aR)-2,3,3a,9a-Tetrahydro-3-hydroxy-6-imino-6H-furo[2′,3′:4,5]oxazolo[3,2-a]pyrimidine-2-methanol Monohydr
CAS Number:10212-25-6
Alternate CAS #
31698-14-3
Molecular Formula:C₉H₁₁N₃O₄ • (HCl)
Appearance:White to Off-White Solid
Melting Point:>230°C (dec.)
Molecular Weight:225.20 + (36.46)
Storage:-20°C
Solubility:Methanol (Slightly), Water (Sparingly)
Category:Standards; Pharmaceutical/API Drug Impurities/Metabolites;
Applications:Ancitabine Hydrochloride is an antineoplastic agent.
References:Ototani, N., Whistler, R.: J. Med. Chem., 17, 535 (1974); Smith, K., et al.: EMBO Mol. Med., 2, 371 (2010);
To ensure the stability of our products, the efficient express delivery service will be used. We also guarantee that the products will be shipped in the box with layers of tapes to protect them against damage. The extremely low temperature products will be wrapped with dried ice, and the low temperature products will be delivered with ice bags. As for the products stored at room temperature, they will not be packed with ice bags or dried ice. Taskcm is committed to providing cost-effective products that facilitate drug delivery with our customers.
Email:sales@ebclink.com

Comments

No comments yet. Why don’t you start the discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *